MedTrace Logo

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

NCT01234012 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2015-03-10

No results posted yet for this study

Summary

The purpose of this study is assess the safety of administering repeated doses of IMF-001, a vaccine, to patients with solid tumors that express NY-ESO-1 antigen. If the vaccine is therapeutically useful, a second goal is to establish the maximum therapeutic dose to treat patients with NY-ESO-1 positive cancers.

Conditions

Interventions

BIOLOGICAL

IMF-001

subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.

Sponsors & Collaborators

  • ImmunoFrontier, Inc.

    lead INDUSTRY

Principal Investigators

  • DAIJU ICHIMARU, BS · ImmunoFrontier, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-11-30
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01234012 on ClinicalTrials.gov